Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson's disease

NeuroToxicology

Volumn 36, Issue , 2013, Pages 63-71

  Morroni, Fabiana ^a   Tarozzi, Andrea ^a   Sita, Giulia ^a   Bolondi, Cecilia ^a   Zolezzi Moraga, Juan Manuel ^a   Cantelli Forti, Giorgio ^a   Hrelia, Patrizia ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

6 Hydroxydopamine; Mouse model; Neuroprotection; Parkinson's disease; Sulforaphane

Indexed keywords

CASPASE 3; GLUTATHIONE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SULFORAPHANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; IMMUNOHISTOCHEMISTRY; MALE; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ACTININ; ADRENERGIC AGENTS; ANALYSIS OF VARIANCE; ANIMALS; APOMORPHINE; CASPASE 3; DISEASE MODELS, ANIMAL; DNA FRAGMENTATION; DOPAMINE AGONISTS; GLUTATHIONE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; ISOTHIOCYANATES; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; ROTAROD PERFORMANCE TEST; ROTATION; TYROSINE 3-MONOOXYGENASE;

MUS;

EID: 84876376158     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2013.03.004     Document Type: Article

References (70)

1. Ahmad A.S., Ansari M.A., Ahmad M., Saleem S., Yousuf S., Hoda M.N., et al. Neuroprotection by crocetin in a hemi-parkinsonian rat model. Pharmacol Biochem Behav 2005, 81(4):805-813.
2. Albarracin S.L., Stab B., Casas Z., Sutachan J.J., Samudio I., Gonzalez J., et al. Effects of natural antioxidants in neurodegenerative disease. Nutr Neurosci 2012, 15(1):1-9.
3. Alessandrini A., Namura S., Moskowitz M.A., Bonventre J.V. MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proc Natl Acad Sci USA 1999, 96(22):12866-12869.
4. Armentero M.T., Fancellu R., Nappi G., Bramanti P., Blandini F. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. Neurobiol Dis 2006, 22(1):1-9.
5. Benassi B., Fanciulli M., Fiorentino F., Porrello A., Chiorino G., Loda M., et al. c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell 2006, 21(4):509-519.
6. Berger K., Przedborski S., Cadet J.L. Retrograde de generation of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats. Brain Res Bull 1991, 26:301-307.
7. Bharath S., Hsu M., Kaur D., Rajagopalan S., Andersen J.K. Glutathione, iron and Parkinson's disease. Biochem Pharmacol 2002, 64(5/6):1037-1048.
8. Blandini F., Levandis G., Bazzini E., Nappi G., Armentero M.T. Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model. Eur J Neurosci 2007, 25:397-405.
9. Chaturvedi R.K., Shukla S., Seth K., Chauhan S., Sinha C., Shukla Y., et al. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Neurobiol Dis 2006, 22(2):421-434.
10. Chen G., Fang Q., Zhang J., Zhou D., Wang Z. Role of the Nrf2-ARE pathway in early brain injury after experimental subarachnoid hemorrhage. J Neurosci Res 2011, 89(4):515-523.
11. Chinta S.J., Andersen J.K. Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione deplection in vitro: implication for Parkinson's disease. Free Radic Biol Med 2006, 41:1442-1448.
12. Chu C.T., Levinthal D.J., Kulich S.M., Chalovich E.M., DeFranco D.B. Oxidative neuronal injury. The dark side of ERK1/2. Eur J Biochem 2004, 271:2060-2066.
13. Cohen G.M. Caspases: the executioners of apoptosis. Biochem J 1997, 326(Pt. 1):1-16.
14. Danilov C.A., Chandrasekaran K., Racz J., Soane L., Zielke C., Fiskum G. Sulforaphane protects astrocytes against oxidative stress and delayed death caused by oxygen and glucose deprivation. Glia 2009, 57(6):645-656.
15. De Bernardo S., Canals S., Casarejos M.J., Solano R.M., Menendez J., Mena M.A. Role of extracellular signal-regulated protein kinase in neuronal cell death induced by glutathione depletion in neuron/glia mesencephalic cultures. J Neurochem 2004, 91(3):667-682.
16. Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol 2000, 62(6):649-671.
17. Fimognari C., Hrelia P. Sulforaphane as a promising molecule for fighting cancer. Mutat Res 2007, 635(2/3):90-104.
18. Fimognari C., Lenzi M., Hrelia P. Chemoprevention of cancer by isothiocyanates and anthocyanins: mechanisms of action and structure-activity relationship. Curr Med Chem 2008, 15(5):440-447.
19. Gao X., Dinkova-kostova A.T., Talalay P. Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane. Proc Natl Acad Sci USA 2001, 98:15221-15226.
20. Hanrott K., Gudmunsen L., O'Neill M.J., Wonnacott S. 6-Hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J Biol Chem 2006, 281(9):5373-5382.
21. Hartmann A., Hunot S., Michel P.P., Muriel M.P., Vyas S., Faucheux B.A., et al. Caspase-3. A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA 2000, 97(6):2875-2880.
22. Hayes J.D., Flanagan J.U., Jowsey I.R. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005, 45:51-88.
23. Innamorato N.G., Rojo A.I., Garcia-Yague A.J., Yamamoto M., de Ceballos M.L., Cuadrado A. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol 2008, 181:680-689.
24. Jakel R.J., Townsend J.A., Kraft A.D., Johnson J.A. Nrf2-mediated protection against 6-hydroxydopamine. Brain Res 2007, 1144:192-201.
25. Jazwa A., Rojo A.I., Innamorato N.G., Hesse M., Fernandez-Ruiz J., Cuadrado A. Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid Redox Signal 2011, 14(12):2347-2360.
26. Jeon B.S., Kholodilov N.G., Oo T.F., Kim S.Y., Tomaselli K.J., Srinivasan A., et al. Activation of caspase-3 in developmental models of programmed cell death in neurons of the substantia nigra. J Neurochem 1999, 73(1):322-333.
27. Jollow D.J., Mitchell J.R., Zampaglione N., Gillette J.R. Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as hepatotoxic metabolite. Pharmacology 1974, 11:151-169.
28. Khan M.M., Raza S.S., Javed H., Ahmad A., Khan A., Islam F., et al. Rutin protects dopaminergic neurons from oxidative stress in an animal model of Parkinson's disease. Neurotox Res 2012, 22(1):1-15.
29. Kulich S.M., Chu C.T. Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease. J Neurochem 2001, 77(4):1058-1066.
30. Kulich S.M., Chu C.T. Role of reactive oxygen species in extracellular signal-regulated protein kinase phosphorylation and 6-hydroxydopamine cytotoxicity. J Biosci 2003, 28(1):83-89.
31. Kuperstein F., Yavin E. ERK activation and nuclear translocation in amyloid-beta peptide- and iron-stressed neuronal cell cultures. Eur J Neurosci 2002, 16(1):44-54.
32. Lang A.E., Lonzano A.M. Parkinson's disease. First of two parts. N Engl J Med 1998, 339:1044-1053.
33. Martí M.J., James C.J., Oo T.F., Kelly W.J., Burke R.E. Early developmental destruction of terminals in the striatal target induces apoptosis in dopamine neurons of the substantia nigra. J Neurosci 1997, 17:2030-2039.
34. Martí M.J., Saura J., Burke R.E., Jackson-Lewis V., Jiménez A., Bonastre M., et al. Striatal 6-hydroxydopamine induces apoptosis of nigral neurons in the adult rat. Brain Res 2002, 958(1):185-191.
35. Matton M.P., Cheng A. Neurohormetic phytochemicals: low-dose toxins that induce adaptive neuronal stress responses. Trends Neurosci 2006, 29:632-639.
36. McCollum M., Ma Z., Cohen E., Leon R., Tao R., Wu J.Y., et al. Post-MPTP treatment with granulocyte colony-stimulating factor improves nigrostriatal function in the mouse model of Parkinson's disease. Mol Neurobiol 2010, 41(2/3):410-419.
37. Meredith G.E., Sonsalla P.K., Chesselet M.F. Animal models of Parkinson disease progression. Acta Neuropathol 2008, 115:385-398.
38. Misiewicz I., Skupinska K., Kowalska E., Lubinski J., Kasuprzycka G.T. Sulforaphan mediated induction of a phase 2 detoxifying enzyme NAD(P)H:quinone reductase and apoptosis in human lymphoblastoid cells. Acta Biochim Pol 2004, 51:711-721.
39. Mizuno K., Kume T., Muto C., Takada-Takatori Y., Izumi Y., Sugimoto H., et al. Gluthatione biosynthesis via activation of the nuclear factor E2-related factor 2 (Nrf2) - antioxidant-response element (ARE) pathway is essential for neuroprotective effects of sulforaphane and 6-(methylsulphnyl) hexyl isothiocyanate. J Pharm Sci 2011, 115(3):320-328.
40. Mladenović A., Perović M., Raicević N., Kanazir S., Rakić L., Ruzdijić S. 6-Hydroxydopamine increases the level of TNFalpha and bax mRNA in the striatum and induces apoptosis of dopaminergic neurons in hemiparkinsonian rats. Brain Res 2004, 996(2):237-245.
41. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., et al. Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain. J Neural Transm 2000, 107(3):335-341.
42. Movsesyan V.A., Yakovlev A.G., Dabaghyan E.A., Stoica B.A., Faden A.I. Ceramide induces neuronal apoptosis through the caspase-9/caspase-3 pathway. Biochem Biophys Res Commun 2002, 299:201-207.
43. Mytilineou C., Kramer B.C., Yabut J.A. Glutathione depletion and oxidative stress. Parkinsonism Relat Disord 2002, 8(6):385-387.
44. Noshita N., Sugawara T., Hayashi T., Lewén A., Omar G., Chan P.H. Copper/zinc superoxide dismutase attenuates neuronal cell death by preventing extracellular signal-regulated kinase activation after transient focal cerebral ischemia in mice. J Neurosci 2002, 22(18):7923-7930.
45. Olanow C.W. The pathogenesis of cell death in Parkinson's disease - 2007. Mov Disord 2007, 22(Suppl. 17):S335-S342.
46. Ouyang M., Shen X. Critical role of ASK1 in the 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells. J Neurochem 2006, 97(1):234-244.
47. Owuor E.D., Kong A.N. Antioxidants and oxidants regulated signal transduction pathways. Biochem Pharmacol 2002, 64(5/6):765-770.
48. Paul G., Meissner W., Rein S., Harnack D., Winter C., Hosmann K., et al. Ablation of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson's disease. Exp Neurol 2004, 185(2):272-280.
49. Ping Z., Liu W., Kang Z., Cai J., Wang Q., Cheng N., et al. Sulforaphane protects brains against hypoxic-ischemic injury through induction of Nrf2-dependent phase 2 enzyme. Brain Res 2010, 1343:178-185.
50. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., et al. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 1995, 67:631-647.
51. Sánchez-Iglesias S., Méndez-Alvarez E., Iglesias-González J., Muñoz-Patiño A., Sánchez-Sellero I., Labandeira-García J.L., et al. Brain oxidative stress and selective behaviour of aluminium in specific areas of rat brain: potential effects in a 6-OHDA-induced model of Parkinson's disease. J Neurochem 2009, 109(3):879-888.
52. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59:401-415.
53. Sharma S., Nemecz S.K., Zhu S., Steele V.E. Identification of chemiopreventive agents by screening for identification of glutathione-S-transferase as a biomarker. Methods Cell Sci 1997, 19:49-52.
54. Stanciu M., Wang Y., Kentor R., Burke N., Watkins S., Kress G., et al. Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J Biol Chem 2000, 275(16):12200-12206.
55. Subramaniam S., Unsicker K. ERK and cell death: ERK1/2 in neuronal death. FEBS J 2010, 277(1):22-29.
56. Suzuki Y.J., Forman H.J., Sevanian A. Oxidants as stimulators of signal transduction. Free Radic Biol Med 1997, 22(1/2):269-285.
57. Tarozzi A., Morroni F., Hrelia S., Angeloni C., Marchesi A., Cantelli-Forti G., et al. Neuroprotective effects of anthocyanins and their in vivo metabolites in SH-SY5Y cells. Neurosci Lett 2007, 424(1):36-40.
58. Tarozzi A., Morroni F., Merlicco A., Hrelia S., Angeloni C., Cantelli-Forti G., et al. Sulforaphane a san inducer of glutathione prevents oxidative stress-induced cell death in a dopaminergic-like neuroblastoma cell line. J Neurochem 2009, 111(5):1161-1171.
59. Tarozzi A., Morroni F., Bolondi C., Sita G., Hrelia P., Djemil A., et al. Neuroprotective effects of erucin against 6-hydroxydopamine-induced oxidative damage in a dopaminergic-like neuroblastoma cell line. Int J Mol Sci 2012, 13(9):10899-10910.
60. Tatton N.A. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol 2000, 166(1):29-43.
61. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970, 24:485-493.
62. Whishaw I.Q., Li K., Whishaw P.A., Gorny B., Metz G.A. Use of rotorod as a method for the qualitative analysis of walking in rat. J Vis Exp 2008, 22:1030.
63. Xia R., Mao Z.H. Progression of motor symptoms in Parkinson's disease. Neurosci Bull 2012, 28(1):39-48.
64. Yacoubian T.A., Standaert D.G. Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta 2009, 1792(7):676-687.
65. Zafar K.S., Siddiqui A., Sayeed I., Ahmad M., Saleem S., Islam F. Protective effect of adenosine in rat model of Parkinson's disease: neurobehavioral and neurochemical evidences. J Chem Neuroanat 2003, 26(2):143-151.
66. Zeevalk G.D., Razmpour R., Bernard L.P. Glutathione and Parkinson's disease: is it an elephant in the room. Biomed Pharmacother 2008, 62:236-249.
67. Zhao J., Kobori N., Aronowski J., Dash P.K. Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents. Neurosci Lett 2006, 393:108-112.
68. Zhao X., Sun G., Zhang J., Strong R., Dash P.K., Kan Y.W., et al. Transcription factor Nrf2 protects the brain from damage produced by intracerebral hemorrhage. Stroke 2007, 38:3280-3286.
69. Zhao X., Moore A.N., Redell J.B., Dash P.K. Enhancing expression of Nrf2-driven genes protects the blood brain barrier after brain injury. J Neurosci 2007, 27:10240-10248.
70. Zhu J.H., Kulich S.M., Oury T.D., Chu C.T. Cytoplasmic aggregates of phosphorylated extracellular signal-regulated protein kinases in Lewy body diseases. Am J Pathol 2002, 161(6):2087-2098.